Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.

Zhao S, Kanagal-Shamanna R, Navsaria L, Chi Young OK, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P.

Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25796. [Epub ahead of print]

PMID:
32239765
2.

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.

Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML.

Blood Adv. 2020 Mar 24;4(6):1038-1050. doi: 10.1182/bloodadvances.2019001396.

3.

CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.

Shen J, Medeiros LJ, Li S, Wang SA, Lin P, Khanlari M, Iyer SP, Yin CC, Tang G, Jorgensen JL, Hu S, Miranda RN, Xu J.

Hum Pathol. 2020 Feb 4;98:1-9. doi: 10.1016/j.humpath.2020.01.005. [Epub ahead of print]

PMID:
32032618
4.

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.

Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS.

Leuk Lymphoma. 2020 Jan 23:1-8. doi: 10.1080/10428194.2020.1716221. [Epub ahead of print]

PMID:
31971032
5.

Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues.

Lyapichev KA, Sukswai N, Strati P, Iyer SP, Medeiros LJ, Miranda RN.

Ann Diagn Pathol. 2019 Dec;43:151398. doi: 10.1016/j.anndiagpath.2019.08.002. Epub 2019 Aug 3. No abstract available.

PMID:
31630065
6.

PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.

Shen J, Li S, Medeiros LJ, Lin P, Wang SA, Tang G, Yin CC, You MJ, Khoury JD, Iyer SP, Miranda RN, Xu J.

Mod Pathol. 2020 Mar;33(3):324-333. doi: 10.1038/s41379-019-0336-3. Epub 2019 Aug 5.

PMID:
31383967
7.

Defining specific allergens for improved component-resolved diagnosis of shrimp allergy in adults.

Johnston EB, Kamath SD, Iyer SP, Pratap K, Karnaneedi S, Taki AC, Nugraha R, Schaeffer PM, Rolland JM, O'Hehir RE, Lopata AL.

Mol Immunol. 2019 Aug;112:330-337. doi: 10.1016/j.molimm.2019.05.006. Epub 2019 Jun 24.

PMID:
31247376
8.

Complete Response to R-EPOCH in Primary Cardiac Lymphoma.

Anand K, Pingali SR, Trachtenberg B, Iyer SP.

Case Rep Hematol. 2019 Apr 10;2019:7690430. doi: 10.1155/2019/7690430. eCollection 2019.

9.

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.

Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS.

Blood Adv. 2019 May 14;3(9):1356-1367. doi: 10.1182/bloodadvances.2018029140.

10.

Fast-track Protocol versus Conventional Protocol on Patient Outcome: A Randomized Clinical Trial.

Iyer SP, Kareem Z.

Niger J Surg. 2019 Jan-Jun;25(1):36-41. doi: 10.4103/njs.NJS_34_17.

11.

Triple-hit lymphoma of the cavernous sinus.

Tran J, Vickers A, Ponce CP, Iyer SP, Lee AG.

Can J Ophthalmol. 2019 Apr;54(2):e61-e66. doi: 10.1016/j.jcjo.2018.06.007. Epub 2018 Aug 28. No abstract available.

PMID:
30975363
12.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ.

Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.

13.

Characteristics and Treatment of Advanced Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Collins MS, Miranda RN, Medeiros LJ, Silva de Meneses MP, Iyer SP, Butler CE, Liu J, Clemens MW.

Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):41S-50S. doi: 10.1097/PRS.0000000000005568.

PMID:
30817555
14.

Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential.

Anand K, Kumar P, Pingali SR, Pati D, Iyer SP.

Am J Hematol. 2019 Mar;94(3):E82-E85. doi: 10.1002/ajh.25380. Epub 2019 Jan 10. No abstract available.

15.

Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy.

Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e51-e61. doi: 10.1016/j.clml.2018.09.002. Epub 2018 Sep 10.

16.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D.

Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6.

17.

Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.

Qin Q, Nan X, Miller T, Fisher R, Teh B, Pandita S, Farach AM, Pingali SR, Pandita RK, Butler EB, Pandita TK, Iyer SP.

Radiat Res. 2018 Sep;190(3):322-329. doi: 10.1667/RR15048.1. Epub 2018 Jun 27.

18.

SMARCAD1 Phosphorylation and Ubiquitination Are Required for Resection during DNA Double-Strand Break Repair.

Chakraborty S, Pandita RK, Hambarde S, Mattoo AR, Charaka V, Ahmed KM, Iyer SP, Hunt CR, Pandita TK.

iScience. 2018 Apr 27;2:123-135. doi: 10.1016/j.isci.2018.03.016.

19.

Notice of Retraction and Replacement. Karalunas et al. Subtyping attention-deficit/hyperactivity disorder using temperament dimensions: toward biologically based nosologic criteria. JAMA Psychiatry. 2014;71(9):1015-1024.

Karalunas SL, Fair D, Musser ED, Aykes K, Iyer SP, Nigg JT.

JAMA Psychiatry. 2018 Apr 1;75(4):408-409. doi: 10.1001/jamapsychiatry.2018.0013. No abstract available.

20.

Cross Talk between Radiation and Immunotherapy: The Twain Shall Meet.

Iyer SP, Hunt CR, Pandita TK.

Radiat Res. 2018 Mar;189(3):219-224. doi: 10.1667/RR14941.1. Epub 2017 Dec 20. Review.

21.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.

Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, Iyer SP, Bearss D, Bhalla KN.

Leukemia. 2017 Jul;31(7):1658. doi: 10.1038/leu.2017.77. Epub 2017 Mar 21.

PMID:
28322226
22.

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.

Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B.

Hematol Oncol. 2017 Dec;35(4):914-917. doi: 10.1002/hon.2320. Epub 2016 Jul 12. No abstract available.

23.

Challenges in the Operationalization of Mental Health Quality Measures: An Assessment of Alternatives.

Iyer SP, Spaeth-Rublee B, Pincus HA.

Psychiatr Serv. 2016 Oct 1;67(10):1057-1059. Epub 2016 Jun 15.

PMID:
27301768
24.

Improving Health Care for the Future Uninsured in Los Angeles County: A Community-Partnered Dialogue.

Iyer SP, Jones A, Talamantes E, Barnert ES, Kanzaria HK, Detz A, Daskivich TJ, Jones L, Ryan GW, Mahajan AP.

Ethn Dis. 2015 Nov 5;25(4):487-94. doi: 10.18865/ed.25.4.487.

25.

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K.

Clin Cancer Res. 2016 Feb 15;22(4):868-76. doi: 10.1158/1078-0432.CCR-15-0481. Epub 2015 Oct 12.

27.

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma.

Wen J, Tao W, Hao S, Iyer SP, Zu Y.

Leukemia. 2016 Apr;30(4):987-91. doi: 10.1038/leu.2015.216. Epub 2015 Aug 5. No abstract available.

PMID:
26242462
28.

Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.

Zhao N, Pei SN, Qi J, Zeng Z, Iyer SP, Lin P, Tung CH, Zu Y.

Biomaterials. 2015 Oct;67:42-51. doi: 10.1016/j.biomaterials.2015.07.025. Epub 2015 Jul 15.

29.

Consumer-Involved Participatory Research to Address General Medical Health and Wellness in a Community Mental Health Setting.

Iyer SP, Pancake LS, Dandino ES, Wells KB.

Psychiatr Serv. 2015 Dec 1;66(12):1268-70. doi: 10.1176/appi.ps.201500157. Epub 2015 Jul 15.

PMID:
26174950
30.

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.

Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, Sharma S, Bradner JE, Bhalla KN.

Leukemia. 2016 Feb;30(2):504-8. doi: 10.1038/leu.2015.142. Epub 2015 Jun 15. No abstract available.

31.

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.

Iyer SP, Foss FF.

Oncologist. 2015 Sep;20(9):1084-91. doi: 10.1634/theoncologist.2015-0043. Epub 2015 Jun 22. Review.

32.

Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.

Seggewiss-Bernhardt R, Bargou RC, Goh YT, Stewart AK, Spencer A, Alegre A, Bladé J, Ottmann OG, Fernandez-Ibarra C, Lu H, Pain S, Akimov M, Iyer SP.

Cancer. 2015 Jul 1;121(13):2185-92. doi: 10.1002/cncr.29339. Epub 2015 Mar 24.

33.

Characterizing heterogeneity in children with and without ADHD based on reward system connectivity.

Costa Dias TG, Iyer SP, Carpenter SD, Cary RP, Wilson VB, Mitchell SH, Nigg JT, Fair DA.

Dev Cogn Neurosci. 2015 Feb;11:155-74. doi: 10.1016/j.dcn.2014.12.005.

34.

Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.

Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B.

Ann Oncol. 2015 Apr;26(4):774-9. doi: 10.1093/annonc/mdv010. Epub 2015 Jan 20.

35.

Health screening, counseling, and hypertension control for people with serious mental illness at primary care visits.

Iyer SP, Young AS.

Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):60-6. doi: 10.1016/j.genhosppsych.2014.10.003. Epub 2014 Oct 16.

PMID:
25480463
36.

A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.

Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC.

Br J Haematol. 2014 Nov;167(3):366-75. doi: 10.1111/bjh.13056. Epub 2014 Aug 19.

PMID:
25139740
37.

Subtyping attention-deficit/hyperactivity disorder using temperament dimensions: toward biologically based nosologic criteria.

Karalunas SL, Fair D, Musser ED, Aykes K, Iyer SP, Nigg JT.

JAMA Psychiatry. 2014 Sep;71(9):1015-24. doi: 10.1001/jamapsychiatry.2014.763.

38.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.

Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN.

Leukemia. 2014 Nov;28(11):2155-64. doi: 10.1038/leu.2014.119. Epub 2014 Apr 4. Erratum in: Leukemia. 2017 Jul;31(7):1658.

39.

Organizing heterogeneous samples using community detection of GIMME-derived resting state functional networks.

Gates KM, Molenaar PC, Iyer SP, Nigg JT, Fair DA.

PLoS One. 2014 Mar 18;9(3):e91322. doi: 10.1371/journal.pone.0091322. eCollection 2014.

40.

Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton.

Iyer SP, Nikkel LE, Nishiyama KK, Dworakowski E, Cremers S, Zhang C, McMahon DJ, Boutroy S, Liu XS, Ratner LE, Cohen DJ, Guo XE, Shane E, Nickolas TL.

J Am Soc Nephrol. 2014 Jun;25(6):1331-41. doi: 10.1681/ASN.2013080851. Epub 2014 Feb 7.

41.

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.

Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN.

Mol Cancer Ther. 2014 May;13(5):1142-54. doi: 10.1158/1535-7163.MCT-13-0770. Epub 2014 Jan 16.

42.

WTAP is a novel oncogenic protein in acute myeloid leukemia.

Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA, Penalva LO, Uren PJ, Suresh U, Carew JS, Karnad AB, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S.

Leukemia. 2014 May;28(5):1171-4. doi: 10.1038/leu.2014.16. Epub 2014 Jan 13. No abstract available. Erratum in: Leukemia. 2014 Dec;28(12):2427. Proia, D [Corrected to Proia, D A].

43.

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP.

Invest New Drugs. 2014 Jun;32(3):489-99. doi: 10.1007/s10637-013-0050-9. Epub 2013 Dec 20.

44.

Cryptococcal meningitis presenting as sinusitis in a renal transplant recipient.

Iyer SP, Movva K, Wiebel M, Chandrasekar P, Alangaden G, Carron M, Tranchida P, Revankar SG.

Transpl Infect Dis. 2013 Oct;15(5):E187-90. doi: 10.1111/tid.12128. Epub 2013 Aug 27.

PMID:
24034280
45.

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.

Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. doi: 10.1007/s00280-013-2249-z. Epub 2013 Aug 15.

46.

Inferring functional connectivity in MRI using Bayesian network structure learning with a modified PC algorithm.

Iyer SP, Shafran I, Grayson D, Gates K, Nigg JT, Fair DA.

Neuroimage. 2013 Jul 15;75:165-175. doi: 10.1016/j.neuroimage.2013.02.054. Epub 2013 Mar 7.

47.

Pancreas-kidney transplantation is associated with reduced fracture risk compared with kidney-alone transplantation in men with type 1 diabetes.

Nikkel LE, Iyer SP, Mohan S, Zhang A, McMahon DJ, Tanriover B, Cohen DJ, Ratner L, Hollenbeak CS, Rubin MR, Shane E, Nickolas TL; CURE Group (The Columbia University Renal Epidemiology Group).

Kidney Int. 2013 Mar;83(3):471-8. doi: 10.1038/ki.2012.430. Epub 2013 Jan 2.

48.

Reward circuit connectivity relates to delay discounting in children with attention-deficit/hyperactivity disorder.

Costa Dias TG, Wilson VB, Bathula DR, Iyer SP, Mills KL, Thurlow BL, Stevens CA, Musser ED, Carpenter SD, Grayson DS, Mitchell SH, Nigg JT, Fair DA.

Eur Neuropsychopharmacol. 2013 Jan;23(1):33-45. doi: 10.1016/j.euroneuro.2012.10.015. Epub 2012 Dec 1.

50.

Excision of carbuncle with primary split-thickness skin grafting as a new treatment modality.

Iyer SP, Kadam P, Gore MA, Subramaniyan P.

Int Wound J. 2013 Dec;10(6):697-702. doi: 10.1111/j.1742-481X.2012.01049.x. Epub 2012 Aug 10.

PMID:
22883561

Supplemental Content

Support Center